Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration the class of 2008

JAMA Internal Medicine

Volumn 174, Issue 1, 2014, Pages 90-95

  Moore, Thomas J ^a,b   Furberg, Curt D ^c  

^a INSTITUTE FOR SAFE MEDICATION PRACTICES   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; BENDAMUSTINE; CARCINOGEN; CERTOLIZUMAB PEGOL; CLEVIDIPINE; DEGARELIX; DESVENLAFAXINE; DIFLUPREDNATE; ELTROMBOPAG; ETRAVIRINE; FESOTERODINE; FOSPROPOFOL; HARKOSERIDE; MUTAGENIC AGENT; PLERIXAFOR; PRESTIQ; RILONACEPT; ROMIPLOSTIM; RUFINAMIDE; SILODOSIN; TAPENTADOL; TERATOGENIC AGENT; TETRABENAZINE; UNCLASSIFIED DRUG; VENLAFAXINE;

ARTICLE; BIRTH DEFECT; CANCER RISK; CONTROLLED CLINICAL TRIAL (TOPIC); CYTOPENIA; DATA BASE; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INFORMATION; DRUG MARKETING; DRUG SAFETY; FETUS DISEASE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IN VITRO STUDY; LAW; LIVER TOXICITY; NONHUMAN; OPPORTUNISTIC INFECTION; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; RISK MANAGEMENT; STEVENS JOHNSON SYNDROME; SUICIDE;

CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG DISCOVERY; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84892390898     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.11813     Document Type: Article

References (17)

1. 21 USC §355. New drugs. www.gpo.gov/fdsys/pkg/USCODE-2010-title21/ html/USCODE-2010-title21-chap9-subchapV-partA-sec355.htm. Accessed April 22, 2013.
2. 21 CFR §314.3. Applications for FDA approval to market a new drug: definitions. www.gpo.gov/fdsys/pkg/CFR-2003-title21-vol5/pdf/CFR-2003-title21- vol5-sec314-3.pdf. Accessed April 22, 2013.
3. US Food and Drug Administration. Speeding access to important new therapies - fast track, accelerated approval and priority review. www.fda.gov/forconsumers/byaudience/forpatientadvocates/ speedingaccesstoimportantnewtherapies/ucm128291.htm. Accessed September 20, 2013.
4. International Conference on Harmonization. Guidance for industry: the extent of population exposure to assess clinical safety: for drugs intended for long-term treatment of non-life-threatening conditions. www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073083.pdf. Accessed March 22, 2013.
5. 21 USC §355c. Research into pediatric uses for drugs and biological products. www.gpo.gov/fdsys/pkg/USCODE-2012-title21/pdf/USCODE-2012-title21- chap9-subchapV-partA-sec355c.pdf. Accessed September 20, 2013.
6. 21 USC §355-1. Risk evaluation and mitigation strategies. www.gpo.gov/fdsys/pkg/USCODE-2012-title21/pdf/USCODE-2012-title21-chap9- subchapV-partA-sec355-1.pdf. Accessed September 20, 2013.
7. President's Council of Advisors on Science and Technology. Report to the President on Propelling Innovation in Drug Discovery, Development and Evaluation. Washington, DC: Executive Office of the President of the United States; September 1, 2012.
8. US Food and Drug Administration. Driving Biomedical Innovation: Initiatives to Improve Products for Patients. October 2011. www.fda.gov/ AboutFDA/ReportsManualsForms/Reports/ucm274333.htm. Accessed April 22, 2013.
9. Creating an alternative approval pathway for certain drugs intended to address unmet need. Fed Regist. 2013;78(10):3005-3008. www.gpo.gov/fdsys/pkg/FR- 2013-01-15/pdf/2013-00607.pdf. Accessed August 27, 2013.
10. US Food and Drug Administration. Guidance for industry: enrichment strategies for clinical trials to support approval of human drugs and biological products: draft guidance. December 2012. www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM332181.pdf. Accessed April 22, 2013.
11. US Food and Drug Administration. Guidance for industry: Alzheimer's disease: developing drugs for the treatment of early stage disease: draft guidance. February 2013. www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM338287.pdf. Accessed April 22, 2013.
12. US Food and Drug Administration. Drug approvals and databases. www.fda.gov/Drugs/InformationOnDrugs/default.htm. Accessed April 23, 2013.
13. Daily Med Current Medication Information. US National Library of Medicine website. http://dailymed.nlm.nih.gov/dailymed/about.cfm. Accessed April 23, 2013.
14. 26 USC §45C. Clinical testing expenses for certain drugs for rare diseases or conditions. www.gpo.gov/fdsys/pkg/USCODE-2011-title26/pdf/USCODE- 2011-title26-subtitleA-chap1-subchapA-partIV-subpartD-sec45C.pdf. Accessed August 27, 2013.
15. 21 USC §360cc. Protection for drugs for rare diseases or conditions. www.gpo.gov/fdsys/pkg/USCODE-2011-title21/pdf/USCODE-2011-title21-chap9- subchapV-partB-sec360cc.pdf. Accessed August 27, 2013.
16. Moore TJ, Singh S, Furberg CD The FDA and new safety warnings. Arch Intern Med. 2012;172(1):78-80.
17. Lester J, Neyarapally GA, Lipowski E, Graham C.F., Hall M., Dal Pan G. Evaluation of FDA safety-related drug label changes in 2010. Pharmacoepidemiol Drug Saf. 2013;22(3):302-305.